Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 1/20 | 0.44 |
| ▸ | CA2 | P00918 | 1/20 | 0.44 |
| ▸ | CCNE2 | O96020 | 2/20 | 0.42 |
| ▸ | CCNE1 | P24864 | 2/20 | 0.42 |
| ▸ | CDK2 | P24941 | 2/20 | 0.42 |
| ▸ | CCNB2 | O95067 | 1/20 | 0.42 |
| ▸ | CDK1 | P06493 | 1/20 | 0.42 |
| ▸ | CDK4 | P11802 | 1/20 | 0.42 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.42 |
| ▸ | CCND1 | P24385 | 1/20 | 0.42 |
| ▸ | CCNB3 | Q8WWL7 | 1/20 | 0.42 |
| ▸ | LCK | P06239 | 6/20 | 0.41 |
| ▸ | FFAR2 | O15552 | 1/20 | 0.39 |
| ▸ | FPR3 | P25089 | 1/20 | 0.37 |
| ▸ | FPR2 | P25090 | 1/20 | 0.37 |
| ▸ | METAP1 | P53582 | 1/20 | 0.37 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31282374 | 0.86 | FFAR2 (0.52) | CA1CA2CCNE2CCNE1CDK2 | |
| SCHEMBL3013536 | 0.82 | CA1 (0.41) | CA1CA2CCNE2CCNE1CDK2 | |
| SCHEMBL15172488 | 0.81 | CA1 (0.40) | CA1CA2CCNE2CCNE1CDK2 | |
| SCHEMBL29276894 | 0.79 | CA1 (0.41) | CA1CA2CCNE2CCNE1CDK2 | |
| SCHEMBL12241503 | 0.79 | RAB9A (0.52) | CA1CA2CCNE2CCNE1CDK2 | |
| SCHEMBL13266901 | 0.78 | CA1 (0.47) | CA1CA2CCNE2CCNE1CDK2 | |
| SCHEMBL13039 | 0.78 | FPR3 (0.54) | CA1CA2CCNE2CCNE1CDK2 | |
| SCHEMBL20877512 | 0.78 | CA1 (0.47) | CA1CA2CCNE2CCNE1CDK2 | |
| SCHEMBL27819346 | 0.78 | CA1 (0.47) | CA1CA2CCNE2CCNE1CDK2 | |
| SCHEMBL15921777 | 0.78 | CA1 (0.50) | CA1CA2CCNE2CCNE1CDK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 50 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240208960-A1 | AMINOTHIAZOLE COMPOUNDS AS C-KIT INHIBITORS | TAKEDA PHARMACEUTICALS U.S.A., INC. | 2024-06-27 | — | — | US | disclosed |
| US-20240208960-A1 | AMINOTHIAZOLE COMPOUNDS AS C-KIT INHIBITORS | TAKEDA PHARMACEUTICALS U.S.A., INC. | 2024-06-27 | — | — | US | disclosed |
| US-20240208960-A1 | AMINOTHIAZOLE COMPOUNDS AS C-KIT INHIBITORS | TAKEDA PHARMACEUTICALS U.S.A., INC. | 2024-06-27 | — | — | US | disclosed |
| CN-117105922-A | Aminothiazole compounds as C-KIT inhibitors | 阿瑞雅德制药公司 | 2023-11-24 | — | — | CN | disclosed |
| CN-117050032-A | Aminothiazole compounds as C-KIT inhibitors | 阿瑞雅德制药公司 | 2023-11-14 | — | — | CN | disclosed |
| US-11753404-B2 | Aminothiazole compounds as c-Kit inhibitors | ARIAD PHARMACEUTICALS, INC. (US) | 2023-09-12 | — | — | US | disclosed |
| US-11753404-B2 | Aminothiazole compounds as c-Kit inhibitors | ARIAD PHARMACEUTICALS, INC. (US) | 2023-09-12 | — | — | US | disclosed |
| US-11753404-B2 | Aminothiazole compounds as c-Kit inhibitors | ARIAD PHARMACEUTICALS, INC. (US) | 2023-09-12 | — | — | US | disclosed |
| CN-110291086-B | Aminothiazole compounds as C-KIT inhibitors | 阿瑞雅德制药公司 | 2023-08-11 | — | — | CN | disclosed |
| EP-3052501-B1 | BICYCLIC ALKYNE DERIVATIVES AND USES THEREOF | AGENCY SCIENCE TECH & RES (SG) | 2022-06-22 | — | — | EP | disclosed |
| US-20100310493-A1 | ACETAMIDE DERIVATIVES AS GLUCOKINASE ACTIVATORS, THEIR PROCESS AND MEDICINAL APPLICATION | ADVINUS THERAPEUTICS PRIVATE LIMITED (IN) | 2010-12-09 | — | — | US | disclosed |
| US-20100310493-A1 | ACETAMIDE DERIVATIVES AS GLUCOKINASE ACTIVATORS, THEIR PROCESS AND MEDICINAL APPLICATION | ADVINUS THERAPEUTICS PRIVATE LIMITED (IN) | 2010-12-09 | — | — | US | disclosed |
| US-20100190766-A1 | ANTIBACTERIAL AGENTS | ACHAOGEN, INC. (US) | 2010-07-29 | — | — | US | disclosed |
| US-20100190766-A1 | ANTIBACTERIAL AGENTS | ACHAOGEN, INC. (US) | 2010-07-29 | — | — | US | disclosed |
| EP-2170814-A2 | ANTIBACTERIAL AGENTS | Achaogen, Inc. (US) | 2010-04-07 | — | — | EP | disclosed |
| CN-101490053-A | Monocyclic Heteroaryl Compounds | ARIAD PHARMA INC (US) | 2009-07-22 | — | — | CN | disclosed |
| US-20090149471-A1 | Monocyclic Heterocyclic Compounds | ARIAD PHARMACEUTICALS, INC. | 2009-06-11 | — | — | US | disclosed |
| US-20090149471-A1 | Monocyclic Heterocyclic Compounds | ARIAD PHARMACEUTICALS, INC. | 2009-06-11 | — | — | US | disclosed |
| WO-2008154642-A2 | ANTIBACTERIAL AGENTS | ACHAOGEN, INC. (US) | 2008-12-18 | — | — | WO | disclosed |
| WO-2008154642-A2 | ANTIBACTERIAL AGENTS | ACHAOGEN, INC. (US) | 2008-12-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11753404-B2 | Aminothiazole compounds as c-Kit inhibitors | KIT, TNNI3K, CKS1B | CA1 3071/4885CA2 1659/4885CCNE2 95/4885 |
| US-20090149471-A1 | Monocyclic Heterocyclic Compounds | CYP11B2, CYP3A5, CYP1A2 | CA1 293/4885CA2 1785/4885CCNE2 240/4885 |
| US-20100310493-A1 | ACETAMIDE DERIVATIVES AS GLUCOKINASE ACTIVATORS, THEIR PROCESS AND MEDICINAL APPLICATION | GCK, GCKR, ALDOA | CA1 1508/4885CA2 378/4885CCNE2 3135/4885 |
| US-20240208960-A1 | AMINOTHIAZOLE COMPOUNDS AS C-KIT INHIBITORS | KIT, TNNI3K, CKS1B | CA1 3071/4885CA2 1659/4885CCNE2 95/4885 |
| US-20100190766-A1 | ANTIBACTERIAL AGENTS | MRPL21, SI, ABCB11 | CA1 4310/4885CA2 3489/4885CCNE2 1822/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.